

Adult CIRB - Early Phase Emphasis Meeting Agenda

January 6, 2026

I Amendment

10397, Optimizing Antibody-Drug Conjugate Therapy through Molecular Analysis for Therapy Choice (ADC MATCH) (Version Date 10/20/25)

II Amendment

10492, Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer (Version Date 11/17/25)

III Continuing Review

10486, Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET) (Version Date 10/27/25)

IV Continuing Review

10559, A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion (Version Date 06/04/25)

V Continuing Review

9681, A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors. (Version Date 07/18/25)



FOR THE NATIONAL CANCER INSTITUTE

VI Continuing Review

AMC-110, Risk-Adapted Therapy for HIV-Associated Anal Cancer (Version Date 07/16/25)
